The deal marks a significant expansion for The9, a company traditionally focused on the gaming sector and its the9bit digital ecosystem. By diversifying into biotechnology, The9 aims to capitalize on the integration of artificial intelligence within pharmaceutical research. Nanyang Biologics utilizes its proprietary Vecura platform, which draws on a library of over one million natural compounds to identify bioactive candidates often overlooked by conventional synthetic methodologies.
In section Releases
The9 Investee Nanyang Biologics Clears Nasdaq Listing Hurdle
Shareholders of RF Acquisition Corp II voted on August 19 to approve a business combination with Nanyang Biologics, pushing the Singapore-based AI drug discovery firm closer to a public listing. The9 Limited, which holds a strategic stake in the company, expects to retain a 15% to 16% interest post-merger.
George Lai, CEO of The9, characterized the shareholder vote as a validation of the firm’s long-term investment strategy. While the business combination remains subject to customary closing conditions, the company is preparing to trade under the ticker symbol NYB. This transition represents a shift in The9’s broader corporate portfolio as it balances its core gaming assets with emerging interests in the AI-driven industrial sector.
Comments (0)
No comments yet. Be the first!